DOTA-Bombesin (1-14) (TFA)

O=C(N[C@@H](C)C(N[C@@H](C(C)C)C(NCC(N[C@H](C(N[C@@H](CC(C)C)C(N[C@H](C(N)=O)CCSC)=O)=O)CC1=CN=CN1)=O)=O)=O)[C@@H](NC([C@H](CCC(N)=O)NC([C@H](CC(N)=O)NC(CNC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCC(N)=O)NC([C@H](CCC2)N2C(CN(CCN(CC3)CC(O)=O)CCN(CCN3CC(O)=O)CC(O)=O)=O)=O)=O)=O)CC(C=C4)=CC=C4O)=O)=O)=O)=O)CC5=CNC6=CC=CC=C56.OC(C(F)(F)F)=O.[x]

[1]Aranda-Lara L, et al. Synthesis and evaluation of Lys¹ (α, γ-Folate) Lys³ (¹⁷⁷Lu-DOTA) -Bombesin (1-14) as a potential theranostic radiopharmaceutical for breast cancer. Appl Radiat Isot. 2016 Jan;107:214-219.